CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

INTRODUCTION: Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cognitive enh...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Nathan, Ismail, Zahinoor, Collins, Rhonda, Desmarais, Philippe, Goodarzi, Zahra, Henri‐Bhargava, Alexandre, Iaboni, Andrea, Kirkham, Julia, Massoud, Fadi, Moser, Andrea, Silvius, James, Watt, Jennifer, Seitz, Dallas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Topic Section
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802736/
https://www.ncbi.nlm.nih.gov/pubmed/35128025
http://dx.doi.org/10.1002/trc2.12099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802736/
https://www.ncbi.nlm.nih.gov/pubmed/35128025
http://dx.doi.org/10.1002/trc2.12099

Ejemplares similares